• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed

    2/2/21 7:05:59 AM ET
    $RDY
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $RDY alert in real time by email
    SC 13G/A 1 d61018dsc13ga.htm SCHEDULE 13G AMENDMENT NO. 1 SCHEDULE 13G Amendment No. 1

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)*

    Dr.Reddy’s Laboratories LTD

    (Name of Issuer)

    Common Stock

    (Title of Class of Securities)

    256135203

    (CUSIP Number)

    December 31, 2020

    (Date of Event Which Requires Filing of this Statement)

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ☑:

    Rule 13d-1(b)

     

    ☐:

    Rule 13d-1(c)

     

    ☐:

    Rule 13d-1(d)

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).


    CUSIP NO. 256135203

     

      1      

     

      NAME OF REPORTING PERSON

     

      Mitsubishi UFJ Financial Group, Inc.

      2    

     

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

      (a)

      (b)

     

      3    

     

      SEC USE ONLY

     

      4    

     

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Tokyo, Japan

    NUMBER OF

    SHARES

      BENEFICIALLY  

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

        5     

      SOLE VOTING POWER

     

      6,184,556

      6     

      SHARED VOTING POWER

     

      -0-

      7     

      SOLE DISPOSITIVE POWER

     

      6,184,556

      8     

      SHARED DISPOSITIVE POWER

     

      -0-

      9      

     

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      6,184,556

    10    

     

      CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

    11    

     

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

      3.7%

    12    

     

      TYPE OF REPORTING PERSON

     

      FI

    * Held in the form of 5,895,119 shares of common stock and 289,437 American Depositary Receipts (“ADRs”), with each ADR representing 1 share of common stock. The common stock is not registered for trading but only in connection with the registration of American Depository Shares which are evidenced by the ADRs.

     

    2


    CUSIP NO. 256135203

     

      1      

     

      NAME OF REPORTING PERSON

     

      Mitsubishi UFJ Trust and Banking Corporation

      2    

     

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

      (a)

      (b)

     

      3    

     

      SEC USE ONLY

     

      4    

     

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Tokyo, Japan

    NUMBER OF

    SHARES

      BENEFICIALLY  

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

        5     

      SOLE VOTING POWER

     

      6,184,556

      6     

      SHARED VOTING POWER

     

      -0-

      7     

      SOLE DISPOSITIVE POWER

     

      6,184,556

      8     

      SHARED DISPOSITIVE POWER

     

      -0-

      9      

     

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      6,184,556

    10    

     

      CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

    11    

     

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

      3.7%

    12    

     

      TYPE OF REPORTING PERSON

     

      FI

    * Held in the form of 5,895,119 shares of common stock and 289,437 American Depositary Receipts (“ADRs”), with each ADR representing 1 share of common stock. The common stock is not registered for trading but only in connection with the registration of American Depository Shares which are evidenced by the ADRs.

     

    3


    CUSIP NO. 256135203

     

      1      

     

      NAME OF REPORTING PERSON

     

      First Sentier Investors Holdings Pty Ltd

      2    

     

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

      (a)

      (b)

     

      3    

     

      SEC USE ONLY

     

      4    

     

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Commonwealth of Australia

    NUMBER OF

    SHARES

      BENEFICIALLY  

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

        5     

      SOLE VOTING POWER

     

      6,103,968

      6     

      SHARED VOTING POWER

     

      -0-

      7     

      SOLE DISPOSITIVE POWER

     

      6,103,968

      8     

      SHARED DISPOSITIVE POWER

     

      -0-

      9      

     

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      6,103,968

    10    

     

      CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

    11    

     

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

      3.7%

    12    

     

      TYPE OF REPORTING PERSON

     

      FI

    * Held in the form of 5,826,106 shares of common stock and 277,862 American Depositary Receipts (“ADRs”), with each ADR representing 1 share of common stock. The common stock is not registered for trading but only in connection with the registration of American Depository Shares which are evidenced by the ADRs.

     

    4


    CUSIP NO. 256135203

     

      1      

     

      NAME OF REPORTING PERSON

     

      Mitsubishi UFJ Kokusai Asset Management Co., Ltd.

      2    

     

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

      (a)

      (b)

     

      3    

     

      SEC USE ONLY

     

      4    

     

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Tokyo, Japan

    NUMBER OF

    SHARES

      BENEFICIALLY  

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

        5     

      SOLE VOTING POWER

     

      24,131

      6     

      SHARED VOTING POWER

     

      -0-

      7     

      SOLE DISPOSITIVE POWER

     

      24,131

      8     

      SHARED DISPOSITIVE POWER

     

      -0-

      9      

     

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      24,131

    10    

     

      CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

    11    

     

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

      0.0%

    12    

     

      TYPE OF REPORTING PERSON

     

      FI

     

    5


    CUSIP NO. 256135203

     

    ITEM  1

           
       (a)                Name of Issuer   
            Dr.Reddy’s Laboratories LTD   
       (b)       Address of Issuer’s Principal Executive Offices   
            8-2-337, Road No.3, Banjara Hills, Hyderabad, Telangana 500034, India   
    ITEM 2        
       (a)       Names of Persons Filing   
            Mitsubishi UFJ Financial Group, Inc. (“MUFG”)   
            Mitsubishi UFJ Trust and Banking Corporation (“MUTB”)   
            First Sentier Investors Holdings Pty Ltd (“FSIHD”)   
            Mitsubishi UFJ Kokusai Asset Management Co., Ltd. (“MUKAM”)   
       (b)       Address of Principal Business Office or, if none, Residence   
            MUFG :   
            7-1 Marunouchi 2-chome, Chiyoda-ku   
            Tokyo 100-8330, Japan   
            MUTB :   
            4-5 Marunouchi 1-chome, Chiyoda-ku   
            Tokyo 100-8212, Japan   
            FSIHD :   
        

       Level 5, Tower Three International Towers Sydney,

       300 Barangaroo Avenue, Barangaroo NSW 2000,

      
            MUKAM :   
        

       12-1 Yurakucho 1-chome, Chiyoda-ku

       Tokyo 100-0006, Japan

      
       (c)       Citizenship   
            MUFG: Tokyo, Japan   
            MUTB: Tokyo, Japan   
            FSIHD: Commonwealth of Australia   
            MUKAM: Tokyo, Japan   
       (d)   

       Title of Class of Securities

      
        

       Common Stock

      

     

    6


    CUSIP NO. 256135203

     

      (e)             CUSIP Number
         256135203(this CUISIP number is for the issuer’s American Depository Shares, not the Common Stock)

    ITEM  3

         If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
     

    MUFG:    

      

    (a)[  ]

      

    Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);

        

    (b)[  ]

      

    Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);

        

    (c)[  ]

      

    Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);

        

    (d)[  ]

      

    Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);

        

    (e)[  ]

      

    An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);

        

    (f)[  ]

      

    An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);

        

    (g)[  ]

      

    A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);

        

    (h)[  ]

      

    A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

        

    (i)[  ]

      

    A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

        

    (j)[Ö]

      

    A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J);

        

    (k)[  ]

      

    Group, in accordance with § 240.13d-1(b)(1)(ii)(K).

        

    If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:    Parent holding company

     

    MUTB:    

      

    (a)[  ]

      

    Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);

        

    (b)[  ]

      

    Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);

        

    (c)[  ]

      

    Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);

        

    (d)[  ]

      

    Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);

        

    (e)[  ]

      

    An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);

        

    (f)[  ]

      

    An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);

        

    (g)[  ]

      

    A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);

     

    7


    CUSIP NO. 256135203

     

         (h)[  ]    A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
         (i)[  ]   

    A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

         (j)[Ö]    A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J);
         (k)[  ]    Group, in accordance with § 240.13d-1(b)(1)(ii)(K).
         If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:     Bank
      FSIHD:        (a)[  ]    Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
         (b)[  ]    Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
         (c)[  ]    Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
         (d)[  ]   

    Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);

        

    (e)[  ]

       An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
         (f)[  ]    An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
         (g)[  ]    A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
         (h)[  ]    A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
        

    (i)[  ]

      

    A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

         (j)[Ö]    A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J);
         (k)[  ]    Group, in accordance with § 240.13d-1(b)(1)(ii)(K).
        

    If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:     Parent holding company

     

    MUKAM:    

      

    (a)[  ]

      

    Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);

        

    (b)[  ]

      

    Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);

        

    (c)[  ]

      

    Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);

        

    (d)[  ]

      

    Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);

     

    8


    CUSIP NO. 256135203

     

        

    (e)[  ]

      

    An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);

        

    (f)[  ]

      

    An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);

        

    (g)[  ]

      

    A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);

        

    (h)[  ]

      

    A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

        

    (i)[  ]

      

    A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

        

    (j)[Ö]

      

    A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J);

        

    (k)[  ]

      

    Group, in accordance with § 240.13d-1(b)(1)(ii)(K).

         If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution: Investment adviser

    ITEM 4

        

    Ownership

         Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
        
        

       For MUFG

      
        

       (a)

      

    Amount beneficially owned:

       6,184,556
        

       (b)

      

    Percent of class:

       3.72%
        

       (c)

      

    Number of shares as to which the person has:

      
           

    (i) Sole power to vote or to direct the vote:

       6,184,556
           

    (ii) Shared power to vote or to direct the vote:

       -0-
           

    (iii) Sole power to dispose or to direct the disposition of:

       6,184,556
           

    (iv) Shared power to dispose or to direct the disposition of:

       -0-
                     

       For MUTB

      
        

       (a)

      

    Amount beneficially owned:

       6,184,556
        

       (b)

      

    Percent of class:

       3.72%
        

       (c)

      

    Number of shares as to which the person has:

      
           

    (i) Sole power to vote or to direct the vote:

       6,184,556
           

    (ii) Shared power to vote or to direct the vote:

       -0-
           

    (iii) Sole power to dispose or to direct the disposition of:

       6,184,556
           

    (iv) Shared power to dispose or to direct the disposition of:

       -0-

     

    9


    CUSIP NO. 256135203

     

        

       For FSIHD

        

       (a)

      

    Amount beneficially owned:

       6,103,968
        

       (b)

      

    Percent of class:

       3.67%
        

       (c)

      

    Number of shares as to which the person has:

      
           

    (i) Sole power to vote or to direct the vote:

       6,103,968
           

    (ii) Shared power to vote or to direct the vote:

       -0-
           

    (iii) Sole power to dispose or to direct the disposition of:

       6,103,968
           

    (iv) Shared power to dispose or to direct the disposition of:

       -0-
        

       For MUKAM

        

       (a)

      

    Amount beneficially owned:

       24,131
        

       (b)

      

    Percent of class:

       0.01%
        

       (c)

      

    Number of shares as to which the person has:

      
           

    (i) Sole power to vote or to direct the vote:

       24,131
           

    (ii) Shared power to vote or to direct the vote:

       -0-
           

    (iii) Sole power to dispose or to direct the disposition of:

       24,131
                                

    (iv) Shared power to dispose or to direct the disposition of:

       -0-

    ITEM 5

                     

    Ownership of Five Percent or Less of a Class

        

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following:     [Ö]

    ITEM 6

        

    Ownership of More than Five Percent on Behalf of Another Person

        

    Not applicable.

    ITEM 7

        

    Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company or Control Person

        

    As of December 31, 2020, MUFG beneficially owns 6,184,556 shares of the issuer indirectly through its subsidiaries as follows: MUTB holds 6,184,556 shares (indirectly through a subsidiary, FSIHD); and (indirectly through a subsidiary, MUKAM). Furthermore, FSIHD holds 6,103,968 shares (indirectly through its subsidiaries as follows; First Sentier Investors (Australia) IM Ltd, First Sentier Investors (Australia) RE Ltd, First Sentier Investors (Singapore) (FKA:First State Investments (Singapore)), First Sentier Investors (UK) IM Limited (FKA: First State Investment Management (UK) Limited) and First Sentier Investors International IM Limited (FKA: First State Investments International Limited)).

    ITEM 8

        

    Identification and Classification of Members of the Group

        

    Not applicable.

     

    10


    CUSIP NO. 256135203

     

    ITEM 9

        

    Notice of Dissolution of Group

        

    Not applicable.

    ITEM 10

                             

    Certifications

        

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

    11


    CUSIP NO. 256135203

     

    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    February 2, 2021

    Mitsubishi UFJ Financial Group, Inc.

    By:

     

    /s/ Riyuuichirou Sakuma

    Name:

     

    Riyuuichirou Sakuma

    Title:

     

    Managing Director,

    Deputy Head of Credit Policy & Planning Division

     

    12


    CUSIP NO. 256135203

     

    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    February 2, 2021

    Mitsubishi UFJ Trust and Banking Corporation

    By:

     

    /s/ Kota Goto

    Name:

     

    Kota Goto

    Title:

     

    Senior Deputy General Manager,

    Asset Management and Investor Services Planning Division

     

    13


    CUSIP NO. 256135203

     

    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    February 2, 2021

    First Sentier Investors Holdings Pty Ltd

    By:

     

    /s/ Yutaka Kawakami

    Name:

     

    Yutaka Kawakami

    Title:

      Deputy CEO

     

    14


    CUSIP NO. 256135203

     

    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    February 2, 2021

    Mitsubishi UFJ Kokusai Asset Management Co., Ltd.

    By:

     

    /s/ Takashi Miyazaki

    Name:

     

    Takashi Miyazaki

    Title:

     

    Executive Officer,

    General Manager of Risk Management Division

     

    15

    Get the next $RDY alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $RDY

    DatePrice TargetRatingAnalyst
    12/19/2024Buy → Neutral
    Nomura
    1/11/2024Buy → Underperform
    Jefferies
    8/29/2023Buy → Hold
    HSBC Securities
    5/18/2023Outperform → Mkt Perform
    Bernstein
    3/17/2023Neutral → Buy
    BofA Securities
    1/30/2023Underweight
    JP Morgan
    11/14/2022Neutral → Underperform
    Credit Suisse
    1/3/2022Neutral
    BofA Securities
    More analyst ratings

    $RDY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Dr. Reddy's downgraded by Nomura

      Nomura downgraded Dr. Reddy's from Buy to Neutral

      12/19/24 8:23:54 AM ET
      $RDY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Dr. Reddy's downgraded by Jefferies

      Jefferies downgraded Dr. Reddy's from Buy to Underperform

      1/11/24 8:20:29 AM ET
      $RDY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Dr. Reddy's downgraded by HSBC Securities

      HSBC Securities downgraded Dr. Reddy's from Buy to Hold

      8/29/23 7:17:57 AM ET
      $RDY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RDY
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Dr. Reddy's Q4 & Full Year FY25 Financial Results

      Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE:RDY, NSEIFSC: DRREDDY) today announced its consolidated financial results for the quarter and year ended March 31, 2025. The information mentioned in this release is based on consolidated financial statements under International Financial Reporting Standards (IFRS). Q4FY25 FY25   Revenues ₹ 85,060 Mn ₹ 325,535 Mn [Up: 20% YoY^; 2% QoQ] [Up: 17% YoY^]     Gross Margin 55.6% 58.5% [Q4FY24: 58.6%; Q3FY25: 58.7%] [FY24: 58.6%]     SG&A Expenses ₹ 24,055 Mn ₹ 93,870 Mn [Up: 17% YoY; Flat QoQ] [Up: 22% YoY]     R&D Expens

      5/9/25 2:53:00 PM ET
      $RDY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bio-Thera and Dr. Reddy's Execute Exclusive Commercialization Agreement for BAT2206, a Proposed Stelara® Biosimilar, and BAT2506, a Proposed Simponi® Biosimilar, for Southeast Asia

      GUANGZHOU, China and HYDERABAD, India, March 27, 2025 /PRNewswire/ -- Bio-Thera Solutions (688177:SH; "Bio-Thera"), a commercial-stage biopharmaceutical company developing a pipeline of innovative therapies and biosimilars, and Dr. Reddy's Laboratories SA, wholly-owned subsidiary of Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE:RDY, NSEIFSC: DRREDDY, along with its subsidiaries hereafter referred to as ", Dr. Reddy', s", ), announce today they have reached commercialization and license agreements for BAT2206, a proposed Stelara® biosimilar, and BAT2506, a proposed Simponi® biosimilar.

      3/27/25 11:47:00 AM ET
      $RDY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alvotech and Dr. Reddy's Announce FDA Acceptance of Biologic License Application for AVT03, a Proposed Biosimilar to Prolia® and Xgeva®

      Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE:RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as "Dr. Reddy's") and Alvotech (NASDAQ:ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that the U.S. Food and Drug Administration (FDA) has accepted a 351(k) Biologic License Application (BLA) submission for AVT03, developed by Alvotech, a proposed biosimilar of Prolia® (denosumab) and Xgeva® (denosumab). "The FDA's filing acceptance of Dr. Reddy's proposed denosumab biosimilar marks an important milestone in bringing this biosimilar medication to more patients t

      3/18/25 8:35:00 AM ET
      $ALVO
      $RDY
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations

    $RDY
    SEC Filings

    See more
    • SEC Form 6-K filed by Dr. Reddy's Laboratories Ltd

      6-K - DR REDDYS LABORATORIES LTD (0001135951) (Filer)

      5/15/25 9:15:27 PM ET
      $RDY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Dr. Reddy's Laboratories Ltd

      6-K - DR REDDYS LABORATORIES LTD (0001135951) (Filer)

      5/14/25 6:18:45 AM ET
      $RDY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Dr. Reddy's Laboratories Ltd

      6-K - DR REDDYS LABORATORIES LTD (0001135951) (Filer)

      5/12/25 6:27:00 AM ET
      $RDY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RDY
    Leadership Updates

    Live Leadership Updates

    See more
    • Henlius and Dr. Reddy's Ink Licensing Deal for HLX15 (investigational daratumumab biosimilar) Expansion in Europe and the U.S.

      SHANGHAI, Feb. 6, 2025 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK) today announced it has entered into a license agreement with Dr. Reddy's Laboratories SA, wholly-owned subsidiary of Dr. Reddy's Laboratories Ltd., (BSE: 500124, NSE: DRREDDY, NYSE:RDY, NSEIFSC: DRREDDY, along with its subsidiaries hereafter referred to as ", Dr. Reddy', s", ) for the company's independently developed investigational daratumumab biosimilar HLX15, a recombinant anti-CD38 fully human monoclonal antibody injection. Dr. Reddy's will gain exclusive rights to commercialize both subcutaneous and intravenous formulation of HLX15 in a total of 43 countries and regions, comprising 42 European countries and

      2/6/25 6:35:00 AM ET
      $RDY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Dr. Reddy's Laboratories Announces the Appointment of Milan Kalawadia to CEO North America

      Dr. Reddy's Laboratories Ltd. ((BSE: 500124, NSE: DRREDDY, NYSE:RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as ", Dr. Reddy', s", )), today announced the appointment of Milan Kalawadia as Chief Executive Officer, North America, and member of the Management Council. As part of the Dr. Reddy's senior leadership team, he will be responsible for the company's North America business and will be based out of the Princeton, New Jersey, U.S. office. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240528120424/en/Milan Kalawadia (Photo: Business Wire) "I am excited to start this next chapter in my journey at Dr

      5/28/24 9:53:00 AM ET
      $RDY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RDY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Dr. Reddy's Laboratories Ltd

      SC 13D/A - DR REDDYS LABORATORIES LTD (0001135951) (Subject)

      7/1/24 6:44:13 AM ET
      $RDY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Dr. Reddy's Laboratories Ltd (Amendment)

      SC 13D/A - DR REDDYS LABORATORIES LTD (0001135951) (Subject)

      5/2/22 2:44:27 PM ET
      $RDY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed

      SC 13G/A - DR REDDYS LABORATORIES LTD (0001135951) (Subject)

      2/2/21 7:05:59 AM ET
      $RDY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RDY
    Financials

    Live finance-specific insights

    See more
    • Dr. Reddy's Q4 & Full Year FY25 Financial Results

      Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE:RDY, NSEIFSC: DRREDDY) today announced its consolidated financial results for the quarter and year ended March 31, 2025. The information mentioned in this release is based on consolidated financial statements under International Financial Reporting Standards (IFRS). Q4FY25 FY25   Revenues ₹ 85,060 Mn ₹ 325,535 Mn [Up: 20% YoY^; 2% QoQ] [Up: 17% YoY^]     Gross Margin 55.6% 58.5% [Q4FY24: 58.6%; Q3FY25: 58.7%] [FY24: 58.6%]     SG&A Expenses ₹ 24,055 Mn ₹ 93,870 Mn [Up: 17% YoY; Flat QoQ] [Up: 22% YoY]     R&D Expens

      5/9/25 2:53:00 PM ET
      $RDY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Dr. Reddy's Q3 & 9MFY25 Financial Results

      Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE:RDY, NSEIFSC: DRREDDY) today announced its consolidated financial results for the quarter and nine months ended December 31, 2024. The information mentioned in this release is based on consolidated financial statements under International Financial Reporting Standards (IFRS). Q3FY25 9MFY25   Revenues ₹ 83,586 Mn ₹ 240,475 Mn [Up: 16% YoY^; 4% QoQ] [Up: 15% YoY^]   Gross Margin 58.7% 59.5% [Q3FY24: 58.5%; Q2FY25: 59.6%] [9MFY24: 58.6%]   SG&A Expenses ₹ 24,117 Mn ₹ 69,815 Mn [Up: 19% YoY; 5% QoQ] [Up: 23% YoY]   R&D Expenses ₹ 6,658 Mn ₹ 20,122 Mn [8.0% o

      1/23/25 12:35:00 PM ET
      $RDY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Dr. Reddy's Q2 & H1FY25 Financial Results

      Dr. Reddy's Laboratories Ltd. ((BSE: 500124, NSE: DRREDDY, NYSE:RDY, NSEIFSC: DRREDDY)) today announced its consolidated financial results for the quarter and half year ended September 30, 2024. The information mentioned in this release is based on consolidated financial statements under International Financial Reporting Standards (IFRS). Q2FY25 H1FY25   Revenues ₹ 80,162 Mn [Up: 17% YoY; 4% QoQ] ₹ 156,889 Mn [Up: 15% YoY]   Gross Margin 59.6% [Q2FY24: 58.7%; Q1FY25: 60.4%] 60.0% [H1FY24: 58.7%]   SG&A Expenses ₹ 23,007 Mn [Up: 22% YoY; 1% QoQ] ₹ 45,698 Mn [Up: 25% YoY]   R&D Expenses ₹ 7,271 Mn [9.1%

      11/5/24 9:59:00 AM ET
      $RDY
      Biotechnology: Pharmaceutical Preparations
      Health Care